Open AccessD-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
Author(s) -
Ruonan Zhang,
Yajing Yang,
Wenjing Dong,
Mingen Lin,
Jing He,
Xinchao Zhang,
Tongguan Tian,
Yunlong Yang,
Kun Chen,
QunYing Lei,
Song Zhang,
Yanping Xu,
Lei Lv
Publication year - 2022
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2114851119
Subject(s) - triple negative breast cancer , immunotherapy , breast cancer , radiation therapy , cancer research , immune checkpoint , immune system , medicine , mannose receptor , cancer , oncology , immunology , biology , biochemistry , macrophage , in vitro
Significance PD-L1 is well known as an immune checkpoint molecule, which suppresses immune surveillance through binding to its receptor PD-1. Intracellular PD-L1 can also protect messenger RNAs of several DNA damage repair–related genes from degradation and enhance tumor resistance to DNA-damaging therapy. Triple-negative breast cancer (TNBC) has the worst prognosis and highest risk of distant relapse in breast cancer and shows resistance to immunotherapy and radiotherapy. In this study, we found that D-mannose can promote the degradation of PD-L1 and significantly enhance immunotherapy and radiotherapy of TNBC. Since TNBC treatment is still a clinical challenge, our findings provide strategies to enhance the therapeutic efficacy of TNBC and may have clinical application.